Investigation Report on China Lentinan Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||334091|
|出版日期||內容資訊||英文 40 Pages
|lentinan的中國市場分析 Investigation Report on China Lentinan Market, 2010-2019|
|出版日期: 2015年07月02日||內容資訊: 英文 40 Pages||
惡性癌症的發病數量全球各國都比3∼5%的速度增加，特別是年輕層的增加率日益升高。估計年度約300萬人，一分鐘便有6人發病。雖然治療上以化療為主流，但生物性多糖體(甜性藥) 的開發·使用也漸漸普及。Lentinan便是這種多糖體之一(免疫反應調節劑的一種)，是擁有可延長生命、改善生活品質(QoL)、副作用小等潛在效果的抗癌劑。最初由日本開發，中國也在1988年上市，但直至近年由於價格居高不下而無法普及 。進入21世紀後國內已可生產，價格也開始下降，因此中國國內的lentinan市場開始擴大。2005年2億人民幣以下的銷售額，之後以11.3%的年平均成長率(CAGR)擴大，到2014年達到了4億7300萬人民幣。
Currently, the incidence of malignant cancer is growing at 3%-5% with more and more younger people. The number of new cases of cancer exceeds 3 million each year with six confirmed cases every one minute. And bad living habits and changed environment have become the main risk factors of cancer.
Carbohydrate drug is the bioactive carbohydrate and its derivatives isolated from animals, plants, microbes and sea creatures. The diversity of carbohydrate structure determines the diversity of carbohydrate drug's bioactivity. One category of carbohydrate drugs is the immunoregulatory anti-tumor polysaccharide isolated from plants and microbes. Although chemotherapy drugs are the most common drugs for malignant cancer in the clinic, polysaccharide is with no side effects. Therefore, more and more polysaccharide drugs are used for the treatment or assistive treatment of tumor. Currently, fungi polysaccharide like lentinan, schizophyllan, ganoderan and pachymaran as well as higher plants polysaccharide such as astragalus polysaccharide and panaxan have been widely used in the clinic as immunomodulators and anti-tumor drugs.
As an intravenous biological response modifier, lentinan features potent antitumor effects, remarkably prolonged life, improved life quality and mild side effects. First developed by Japan, lentinan was approved to enter China in 1988. Although the practical use has confirmed lentinan's efficacy, its market size has been limited due to its high price.
After entering the 21st century, lentinan has become able to be produced domestically at a relatively low price. Therefore, its market size grows at an increasing rate, annual sales value rising from less than CNY 200 million in 2005 to CNY 473 million in 2014 and CAGR during this period reaching 11.3%. JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory, Chuang Li Yao Ye, Kanion Pharmaceutical, Nanjing Luye Sike Pharma Co., Ltd and Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory had the largest market share of about 39% for sales value in 2014.
With worsened environmental pollution and lifestyle change brought about by economic development, the incidence of cancer keeps growing. Therefore, the market size of lentinan in China is expected to grow too.